News
The latest news from across neurorehabilitation.
Multiple sclerosis9 JanA combination of 11 proteins can predict long-term disability outcomes in multiple sclerosis (MS) for different individuals, new research has found. The identified proteins could be used to tailor treatments to patients based on the expected severity of the disease. Julia Åkesson is doctoral student at Linköping University and the University of Skövde. The researcher [...]
Research9 JanThe global pursuit of new neurological treatments has been bolstered by a €38 million boost from the European Commission.
EBRAINS is an EU co-funded collaborative project to develop a “digital ecosystem” that enables researchers and clinicians to explore the complexity of the brain at various scales. From here they can derive new solutions for neurological medicines, interventions and technologies. The European Commission has now accepted the “EBRAINS 2.0” proposal, granting €38m for the further development of services of the EBRAINS research infrastructure to 2026.
Parkinson's9 JanScientists believe they may be closing in on a breakthrough in pursuit of earlier diagnosis in Parkinson’s.
In the development of Parkinson’s, the changes that will lead to neurodegeneration take place in the brain long before patients show any symptoms.
But without a test that can detect these changes, it’s difficult to intervene early to more effectively slow disease progression.
Doctors generally must rely on neurological examination and patients’ medical histories when diagnosing Parkinson’s.
Once clinical symptoms appear, however, the disease has already wreaked irreversible damage in the brain.
MND / ALS8 JanResearchers have shed new light on the causes of ALS through an investigation of a molecular anchor called VAP (vesicle-associated membrane protein-associated protein).
When experiencing new things, the structure and function of our neurons and their connections are rapidly being remodeled. This process, known as synaptic plasticity, is critical for us to learn and adapt. However, these changes require a lot of energy. Fortunately, our neurons are well-adapted to support these changes. Biological batteries known as mitochondria are strategically stabilized near sites of synaptic remodeling to ensure a local and efficient energy supply. However, how mitochondria are anchored near synapses was not known. A team of scientists at Max Planck Florida Institute for Neuroscience has now identified a molecular anchor called VAP that stabilises mitochondria near synapses to support these remodeling projects. The identification of VAP as a molecular anchor has particular significance because a mutation in VAP leads to ALS (amyotrophic lateral sclerosis), a progressive motor neuroe degeneration disease. This discovery, published in Nature Communications, not only sheds light on how memories are powered but opens up new research directions into ALS pathology.
Parkinson's21 DecThe new guidelines enable Integrated Care Boards (ICBs) to consider eligibility for a past period of NHS continuing healthcare (CHC), even for those who did not apply, but think they are entitled to funding.
Neuropsychology21 DecQuibim, a company developing imaging biomarkers for precision medicine that has created AI-based software to identify early-stage neurodegenerative diseases, has announced the launch of QP-Brain
News19 DecMore than a third of neurologists in the US believe Bruton’s tyrosine kinase (BTK) inhibitors have huge potential as a future treatment of multiple sclerosis (MS), according to findings from a recent Spherix Global Insights’ survey.
